Therapeutic Response

PD-L1 >= 1%, Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Carboplatin in combination with Cemiplimab and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description